It was a pleasure to speak to Steve Shak from Exact Sciences anto discuss the real-world evidence from a prospective clinical survey of the Oncotype DX Breast Recurrence Score® test, accepted at the ASCO Annual Meeting. Oncotype DX is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
1. Could you give us a brief description of the Oncotype DX Breast Recurrence Score assay and its role in guiding breast cancer treatment decisions? (0:06)
2. Could you summarise the data that its being presented at this year’s ASCO conference? (1:10)
3. What has been the impact of the Oncotype DX test on clinical practice worldwide? (2:21)
4. What progress has been made on making the Oncotype DX test available on a broader international scale? (4:30)
5. What advances do you expect to see in the future with these types of biomarker assays? (7:00)
Speaker disclosure: Steve Shak is Chief Medical Officer of Exact Sciences
Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Breast Cancer
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
Aditya Bardia, ESMO 2020 – Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: the ASCENT Trial
touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s […]
Stephen Johnston, ESMO 2020 – The MonarchE trial and Abemaciclib in High-risk Early Breast Cancer
Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!